J
Jan Schmidt
Researcher at Heidelberg University
Publications - 29
Citations - 4467
Jan Schmidt is an academic researcher from Heidelberg University. The author has contributed to research in topics: Pancreatitis & Pancreatic disease. The author has an hindex of 25, co-authored 29 publications receiving 4080 citations. Previous affiliations of Jan Schmidt include University Hospital Heidelberg & Free University of Berlin.
Papers
More filters
Journal ArticleDOI
A better model of acute pancreatitis for evaluating therapy.
Jan Schmidt,David W. Rattner,Kent B. Lewandrowski,Carolyn C. Compton,Uma Mandavilli,W. T. Knoefel,Andrew L. Warshaw +6 more
TL;DR: The authors conclude that combining minimal intraductal bile acid exposure with intravenous hyperstimulation produces homogeneous pancreatitis of intermediate severity that can be modulated at will and the model provides superior opportunity to study innovative therapy.
Journal ArticleDOI
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.
Arianeb Mehrabi,Arash Kashfi,Hamidreza Fonouni,Peter Schemmer,Bruno M. Schmied,Peter Hallscheidt,Peter Schirmacher,Jürgen Weitz,Helmut Friess,Markus W. Büchler,Jan Schmidt +10 more
TL;DR: A comprehensive review of the literature on HEH is presented, with a focus on clinical outcome after different therapeutic strategies, to suggest LTx is an acceptable option for patients who have HEH with extrahepatic manifestation.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Activation Pattern of Signal Transducers and Activators of Transcription (STAT) Factors in Inflammatory Bowel Diseases
Jonas Mudter,Benno Weigmann,Brigitte Bartsch,Ralf Kiesslich,Dennis Strand,Peter R. Galle,Hans A. Lehr,Jan Schmidt,Markus F. Neurath +8 more
TL;DR: The analysis of STAT activation patterns could serve as a helpful tool to characterize intestinal inflammation and the IL-6/ STAT-3 rather than the IFN-γ/STAT-1 signaling pathway emerges as a key target for the development of future therapeutic concepts in IBD.
Journal ArticleDOI
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya,Raja Atreya,Michael Zimmer,Brigitte Bartsch,Maximilian J. Waldner,Imke Atreya,Helmut Neumann,Kai Hildner,Arthur Hoffman,Ralf Kiesslich,Andreas D. Rink,Tilman T. Rau,Stefan Rose John,Hermann Kessler,Jan Schmidt,Markus F. Neurath,Markus F. Neurath +16 more
TL;DR: Clinically effective anti-TNF antibodies are able to induce T-cell apoptosis in IBD only when mucosal TNFR2(+) T cells are cocultured with mTNF-expressing CD14(+) macrophages.